A Study of MK-6194 (PT101) in Participants With Active Ulcerative Colitis (UC) (MK-6194-002)

PHASE1CompletedINTERVENTIONAL
Enrollment

57

Participants

Timeline

Start Date

October 14, 2021

Primary Completion Date

January 8, 2024

Study Completion Date

July 15, 2024

Conditions
Ulcerative Colitis
Interventions
DRUG

MK-6194

Subcutaneous injection

DRUG

MK-6194-matching placebo

Subcutaneous injection

Trial Locations (17)

1007

PRA Magyarorszag Kutatasi es Fejlesztesi Kft. ( Site 0302), Budapest

2025

ARENSIA Exploratory Medicine ( Site 0401), Chisinau

10117

Charite Research Organisation GmbH ( Site 0201), Berlin

27607

Carolina's GI Research, LLC ( Site 0105), Raleigh

34741

IHS. Health, LLC ( Site 0104), Kissimmee

78229

Pinnacle Clinical Research ( Site 0103), San Antonio

Southern Star Research Institute ( Site 0101), San Antonio

92377

Inland Empire Clinical Trials, LLC ( Site 0102), Rialto

0112

ARENSIA Exploratory Medicine Georgia ( Site 0801), Tbilisi

34-400

Allmedica Badania Kliniczne Sp z o. o. Sp. K. ( Site 0502), Nowy Targ

00-728

WIP Warsaw IBD Point Professor Kierkus ( Site 0501), Warsaw

01135

Arensia Exploratory Medicine GmbH Ukraine ( Site 0701), Kyiv

L34 1BH

MAC Clinical Research Prescot ( Site 0604), Prescot

FY2 0JH

Memory Assessment Clinics Ltd ( Site 0601), Blackpool

S75 3DL

MAC Clinical Research ( Site 0602), Barnsley

LS10 1DU

MAC Clinical Research Centre Leeds ( Site 0603), Leeds

M13 9NQ

MAC Clinical Research Ltd. ( Site 0605), Manchester

All Listed Sponsors
lead

Merck Sharp & Dohme LLC

INDUSTRY

NCT04924114 - A Study of MK-6194 (PT101) in Participants With Active Ulcerative Colitis (UC) (MK-6194-002) | Biotech Hunter | Biotech Hunter